Our $50 million program to advance racial equity
Meet the six partners we’re working with to drive system change.
Since our inception in 2013, AbbVie and the AbbVie Foundation have invested more than $120 million in philanthropic programs that purposefully support diverse communities.
In 2020, we donated $5 million to NAACP Legal Defense and Education Fund and the Equal Justice Initiative to address issues in our criminal justice system. Later that same year, we launched a $50 million, five-year program to support underserved Black communities across the United States. As part of the investment, we’re collaborating with six nonprofit partners to support health and education opportunity in underserved Black communities.
Our $50 million commitment is funded by the AbbVie Foundation a charitable organization established by AbbVie, Inc. The AbbVie Foundation also matches 3:1 employee donations to select nonprofits whose primary mission is to advance racial equity.
AbbVie believes our clinical trials should reflect the populations we serve as we aim to help patients live healthier, longer lives. Ensuring diversity means we can better meet the needs of our patients both today and tomorrow. We are committed to researching and bringing treatment options for diseases that affect patients around the world, including groups of patients who historically have been underserved.
As part of our dedication, AbbVie is committed to being an industry leader in improving clinical research diversity. We rely on real-world data and evidence to guide our diversity and inclusion strategies to ensure participation in AbbVie-sponsored clinical trials appropriately represents patients living with the diseases we are studying. We have been and will continue to analyze our clinical trials to ensure they reflect a diversity in race, ethnicity, age, and gender. To this end, our continuing commitment is as follows:
Black Americans face significant health disparities as a result of systemic inequalities, and as a biopharmaceutical company, it is our moral obligation to do all that we can to help reduce these disparities.
Since we became a company, we have developed new medicines and treatments for diseases that disproportionately impact Black communities, including:
But we are far from finished. We are working to develop new treatments that will significantly advance the standard of care for a number of diseases.